Related references
Note: Only part of the references are listed.Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders
Maartje G. Huijbers et al.
LANCET NEUROLOGY (2022)
Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders
Anna Rostedt Punga et al.
LANCET NEUROLOGY (2022)
The role of serum free light chain as biomarker of Myasthenia Gravis
Caterina Maria Gambino et al.
CLINICA CHIMICA ACTA (2022)
Ectopic germinal centers in the thymus accurately predict prognosis of myasthenia gravis after thymectomy
Joona Sarkkinen et al.
MODERN PATHOLOGY (2022)
Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: a genome-wide association study
Ruth Chia et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)
Distinct roles of ICOS and CD40L in human T-B cell adhesion and antibody production
Zhicui Liu et al.
CELLULAR IMMUNOLOGY (2021)
Serum free light chain reference intervals in an Optilite and their influence on clinical guidelines
Luis J. Morales-Garcia et al.
CLINICAL BIOCHEMISTRY (2021)
Roles of matrix metalloproteinase-7 (MMP-7) in cancer
Hai-Yang Liao et al.
CLINICAL BIOCHEMISTRY (2021)
Effects of thymectomy on late-onset non-thymomatous myasthenia gravis: systematic review and meta-analysis
Jinwei Zhang et al.
ORPHANET JOURNAL OF RARE DISEASES (2021)
Clinical and therapeutic features of myasthenia gravis in adults based on age at onset
Elena Cortes-Vicente et al.
NEUROLOGY (2020)
Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics
Konstantinos Lazaridis et al.
FRONTIERS IN IMMUNOLOGY (2020)
High kappa free light chain is a potential biomarker for double seronegative and ocular myasthenia gravis
Adi Wilf-Yarkoni et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)
The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy
Cinzia Solinas et al.
ESMO OPEN (2020)
Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial
Gil I. Wolfe et al.
LANCET NEUROLOGY (2019)
Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope
Evelina Martinenaite et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Reference intervals and diagnostic ranges for serum free κ and free λ immunoglobulin light chains vary by instrument platform: Implications for classification of patient results in a multi-center study
Steven W. Cotten et al.
CLINICAL BIOCHEMISTRY (2018)
Serological Immunoglobulin-Free Light Chain Profile in Myasthenia Gravis Patients
Umberto Basile et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2018)
Profile of upregulated inflammatory proteins in sera of Myasthenia Gravis patients
Carl Johan Molin et al.
SCIENTIFIC REPORTS (2017)
The role of free kappa and lambda light chains in the pathogenesis and treatment of inflammatory diseases
Mojgan Esparvarinha et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
Genetic heterogeneity within the HLA region in three distinct clinical subgroups of myasthenia gravis
Guher Saruhan-Direskeneli et al.
CLINICAL IMMUNOLOGY (2016)
Myasthenia Gravis
Nils E. Gilhus
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Changes in inflammatory cytokine networks in myasthenia gravis
Akiyuki Uzawa et al.
SCIENTIFIC REPORTS (2016)
Myasthenia gravis: subgroup classification and therapeutic strategies
Nils Erik Gilhus et al.
LANCET NEUROLOGY (2015)
Myasthenia gravis and risks for comorbidity
N. E. Gilhus et al.
EUROPEAN JOURNAL OF NEUROLOGY (2015)
Serum cytokine and chemokine profiles in patients with myasthenia gravis
A. Uzawa et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2014)
Myasthenia gravis: A comprehensive review of immune dysregulation and etiological mechanisms
Sonia Berrih-Aknin et al.
JOURNAL OF AUTOIMMUNITY (2014)
Circulating miRNAs in myasthenia gravis: miR-150-5p as a new potential biomarker
Tanel Punga et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2014)
The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes
Alexander Marx et al.
AUTOIMMUNITY REVIEWS (2013)
Serum free light chain reference values: A critical approach
Sara Altinier et al.
CLINICAL BIOCHEMISTRY (2013)
Risk for Myasthenia Gravis Maps to a 151Pro→Ala Change in TNIP1 and to Human Leukocyte Antigen-B*08
Peter K. Gregersen et al.
ANNALS OF NEUROLOGY (2012)
Antibodies against the main immunogenic region of the acetylcholine receptor correlate with disease severity in myasthenia gravis
Tomoko Masuda et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2012)
Late Onset Myasthenia Gravis Is Associated with HLA DRB1*15:01 in the Norwegian Population
Angelina H. Maniaol et al.
PLOS ONE (2012)
Serum free light chain analysis
Matthew S. Davids et al.
AMERICAN JOURNAL OF HEMATOLOGY (2010)
A systematic review of population based epidemiological studies in Myasthenia Gravis
Aisling S. Carr et al.
BMC NEUROLOGY (2010)
The discovery of Hepatocyte Growth Factor (HGF) and its significance for cell biology, life sciences and clinical medicine
Toshikazu Nakamura et al.
PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES (2010)
Lifetime course of myasthenia gravis
David Grob et al.
MUSCLE & NERVE (2008)
Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance
SV Rajkumar et al.
BLOOD (2005)
Associated conditions in myasthenia gravis:: response to thyrnectorny
JF Téllez-Zenteno et al.
EUROPEAN JOURNAL OF NEUROLOGY (2004)